Form 4: Galectin Therapeutics CEO Exercises, Sells Shares

Galectin Therapeutics Inc. CEO Joel Lewis exercised stock options and sold an equal number of shares under a pre-arranged 10b5-1 plan.

Summary

• Joel Lewis, President and CEO of Galectin Therapeutics Inc. (GALT), reported transactions involving the company's common stock.
• On November 5, 2025, Lewis exercised options to acquire 200 shares of common stock at an exercise price of $2.39 per share.
• Concurrently, on November 5, 2025, Lewis sold 200 shares of common stock at a price of $6.00 per share.
• Both transactions were executed pursuant to a Rule 10b5-1 plan adopted on April 17, 2025, and previously disclosed in the Issuer's Form 10-Q filed on August 14, 2025.
• Following these transactions, Lewis directly beneficially owns 832,592 shares of common stock.
• Lewis also indirectly holds 2,000 shares as a custodian for a minor child under the Uniform Transfer to Minors Act, disclaiming beneficial ownership of these shares.
• After the exercise, Lewis retains 24,230 stock options with an exercise price of $2.39, which vested on December 14, 2018, and expire on December 14, 2027.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the insider realizing a profit on the transaction. However, the overall impact on the company is neutral as it's a small, pre-planned personal transaction by an executive, not indicative of operational performance or strategic shifts.

Positives

• The CEO realized a profit of $3.61 per share ($6.00 sale price $2.39 exercise price) on the 200 shares transacted.
• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating a structured and non-discretionary approach to insider trading.

Negatives

• The sale of shares by a key executive, even if pre-planned, could be perceived by some investors as a lack of confidence, although the amount is small relative to total holdings.

Future Outlook

This Form 4 filing is a disclosure of past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details a routine insider transaction and does not provide information relevant to broader industry trends or competitor analysis.

Stakeholder Impact

• Shareholders: Minimal direct impact due to the small volume of shares traded relative to the company's total outstanding shares and the routine nature of the 10b5-1 plan.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction involving a small number of shares. It does not provide sufficient new information about the company's operational performance, strategic direction, or financial health to warrant a change in investment recommendation. Investors should consider this a standard disclosure and rely on broader fundamental analysis for investment decisions.

Keywords

GALT, Galectin Therapeutics, Joel Lewis, Form 4, Insider Transaction, Stock Options, 10b5-1 Plan, CEO, Equity Sales